Anti-Mouse Ly-6G - DyLight® 650

Leinco Technologies
Product Code: LEI-L289
Product Group: Primary Antibodies
CodeSizePrice
LEI-L289-50ug50 ug£159.00
Quantity:
LEI-L289-100ug100 ug£211.00
Quantity:
LEI-L289-200ug200 ug£291.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rat
Antibody Isotype: IgG2a
Antibody Clonality: Monoclonal
Antibody Clone: 1A8
Regulatory Status: RUO
Target Species: Mouse
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
Ly6G is expressed by neutrophils.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 650
Format:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Mouse Ly-6G (>98%)
Long Description:
Ly6G antibody, clone 1A8, recognizes lymphocyte antigen 6 complex locus G6D (Ly6G; also called Gr-1), a 21-25 kDa glycosylphosphatidylinositol (GPI)-anchored protein1. Ly6G belongs to the lymphocyte antigen-6 (Ly6)/urokinase-type plasminogen activator receptor (uPAR) superfamily, characterized by a Ly6/uPAR (LU) domain-containing a three-fingered structural motif stabilized by disulfide bonds2. Ly6G is expressed by murine neutrophils regardless of location and activation1,4,5. Eosinophils may also express low levels of Ly6G5. There is no human ortholog for Ly6G; however, a structurally related L76/uPAR protein, CD177 (also known as HNA-2a, NB1, or PRV-1) is expressed in human neutrophils and is implicated in neutropenia6. Although the exact function and ligand of Ly6G remain unknown, Ly6G ligation may impair neutrophil migration to sites of inflammation via a β2-integrin-dependent mechanism7.
NCBI Gene:
546644
Target:
Ly-6G

References

1. Fleming TJ, at al. (1993) J Immunol. 151(5):2399-408 2. Tsetlin VI. (2015) Trends Pharmacol Sci. 36(2):109-23 3. Daley JM, et al. (2008) J Leukoc Biol. 83(1):64-70 4. Lee PY, et al. (2013) J Leukoc Biol. 94(4):585-594 5. Percopo CM, et al. (2017) J Leukoc Biol. 101(1):321-328. 6. Stroncek DF. (2007) Curr Opin Hematol. 14(6):688-93 7. Wang JX, et al. (2012) Blood. 120(7):1489-1498